Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome

Paolo Strati, Hagop Kantarjian, Farhad Ravandi, Aziz Nazha, Gautam Borthakur, Naval Daver, Tapan Kadia, Zeev Estrov, Guillermo Garcia-Manero, Marina Konopleva, Trivikram Rajkhowa, Menda Durand, Michael Andreeff, Mark Levis, Jorge Cortes

Research output: Contribution to journalArticle

Abstract

We investigated the combination of midostaurin and azacitidine (AZA) in patients with acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS). Patients received AZA 75 mg m-2 on days 1-7 and midostaurin 25 mg bid (in cohort 1 of phase I) or 50 mg bid (in cohort 2 of Phase I and in Phase II) orally on day 8-21 during the first cycle and continuously thereafter. Fourteen patients were enrolled in the phase I and 40 in the phase II. Overall response rate was 26%. The median remission duration (RD) was 20 weeks and was significantly longer in patients with FLT3 mutations not previously exposed to other FLT3 inhibitors (P=0.05) and in patients not previously transplanted (P=0.01). Thirty-two (59%) patients have died, all of complications related to disease progression. G3-4 nonhematological toxicity was reported in 38 (70%) patients, most frequently infections (56%), ejection fraction reduction (11%), and diarrhea or nausea/vomiting (9% each). The combination of midostaurin and AZA is an effective and safe regimen in patients with AML and high-risk MDS. Patients with FLT3 mutations but not previously exposed to other FLT3 inhibitors and patients not previously transplanted derived the greatest benefit. Further studies with this combination are warranted.

Original languageEnglish (US)
Pages (from-to)276-281
Number of pages6
JournalAmerican Journal of Hematology
Volume90
Issue number4
DOIs
StatePublished - Apr 1 2015
Externally publishedYes

Fingerprint

4'-N-benzoylstaurosporine
Azacitidine
Myelodysplastic Syndromes
Acute Myeloid Leukemia
Mutation

ASJC Scopus subject areas

  • Hematology

Cite this

Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome. / Strati, Paolo; Kantarjian, Hagop; Ravandi, Farhad; Nazha, Aziz; Borthakur, Gautam; Daver, Naval; Kadia, Tapan; Estrov, Zeev; Garcia-Manero, Guillermo; Konopleva, Marina; Rajkhowa, Trivikram; Durand, Menda; Andreeff, Michael; Levis, Mark; Cortes, Jorge.

In: American Journal of Hematology, Vol. 90, No. 4, 01.04.2015, p. 276-281.

Research output: Contribution to journalArticle

Strati, P, Kantarjian, H, Ravandi, F, Nazha, A, Borthakur, G, Daver, N, Kadia, T, Estrov, Z, Garcia-Manero, G, Konopleva, M, Rajkhowa, T, Durand, M, Andreeff, M, Levis, M & Cortes, J 2015, 'Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome', American Journal of Hematology, vol. 90, no. 4, pp. 276-281. https://doi.org/10.1002/ajh.23924
Strati, Paolo ; Kantarjian, Hagop ; Ravandi, Farhad ; Nazha, Aziz ; Borthakur, Gautam ; Daver, Naval ; Kadia, Tapan ; Estrov, Zeev ; Garcia-Manero, Guillermo ; Konopleva, Marina ; Rajkhowa, Trivikram ; Durand, Menda ; Andreeff, Michael ; Levis, Mark ; Cortes, Jorge. / Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome. In: American Journal of Hematology. 2015 ; Vol. 90, No. 4. pp. 276-281.
@article{485f5a1575f74f809fb4b061502aa646,
title = "Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome",
abstract = "We investigated the combination of midostaurin and azacitidine (AZA) in patients with acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS). Patients received AZA 75 mg m-2 on days 1-7 and midostaurin 25 mg bid (in cohort 1 of phase I) or 50 mg bid (in cohort 2 of Phase I and in Phase II) orally on day 8-21 during the first cycle and continuously thereafter. Fourteen patients were enrolled in the phase I and 40 in the phase II. Overall response rate was 26{\%}. The median remission duration (RD) was 20 weeks and was significantly longer in patients with FLT3 mutations not previously exposed to other FLT3 inhibitors (P=0.05) and in patients not previously transplanted (P=0.01). Thirty-two (59{\%}) patients have died, all of complications related to disease progression. G3-4 nonhematological toxicity was reported in 38 (70{\%}) patients, most frequently infections (56{\%}), ejection fraction reduction (11{\%}), and diarrhea or nausea/vomiting (9{\%} each). The combination of midostaurin and AZA is an effective and safe regimen in patients with AML and high-risk MDS. Patients with FLT3 mutations but not previously exposed to other FLT3 inhibitors and patients not previously transplanted derived the greatest benefit. Further studies with this combination are warranted.",
author = "Paolo Strati and Hagop Kantarjian and Farhad Ravandi and Aziz Nazha and Gautam Borthakur and Naval Daver and Tapan Kadia and Zeev Estrov and Guillermo Garcia-Manero and Marina Konopleva and Trivikram Rajkhowa and Menda Durand and Michael Andreeff and Mark Levis and Jorge Cortes",
year = "2015",
month = "4",
day = "1",
doi = "10.1002/ajh.23924",
language = "English (US)",
volume = "90",
pages = "276--281",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome

AU - Strati, Paolo

AU - Kantarjian, Hagop

AU - Ravandi, Farhad

AU - Nazha, Aziz

AU - Borthakur, Gautam

AU - Daver, Naval

AU - Kadia, Tapan

AU - Estrov, Zeev

AU - Garcia-Manero, Guillermo

AU - Konopleva, Marina

AU - Rajkhowa, Trivikram

AU - Durand, Menda

AU - Andreeff, Michael

AU - Levis, Mark

AU - Cortes, Jorge

PY - 2015/4/1

Y1 - 2015/4/1

N2 - We investigated the combination of midostaurin and azacitidine (AZA) in patients with acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS). Patients received AZA 75 mg m-2 on days 1-7 and midostaurin 25 mg bid (in cohort 1 of phase I) or 50 mg bid (in cohort 2 of Phase I and in Phase II) orally on day 8-21 during the first cycle and continuously thereafter. Fourteen patients were enrolled in the phase I and 40 in the phase II. Overall response rate was 26%. The median remission duration (RD) was 20 weeks and was significantly longer in patients with FLT3 mutations not previously exposed to other FLT3 inhibitors (P=0.05) and in patients not previously transplanted (P=0.01). Thirty-two (59%) patients have died, all of complications related to disease progression. G3-4 nonhematological toxicity was reported in 38 (70%) patients, most frequently infections (56%), ejection fraction reduction (11%), and diarrhea or nausea/vomiting (9% each). The combination of midostaurin and AZA is an effective and safe regimen in patients with AML and high-risk MDS. Patients with FLT3 mutations but not previously exposed to other FLT3 inhibitors and patients not previously transplanted derived the greatest benefit. Further studies with this combination are warranted.

AB - We investigated the combination of midostaurin and azacitidine (AZA) in patients with acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS). Patients received AZA 75 mg m-2 on days 1-7 and midostaurin 25 mg bid (in cohort 1 of phase I) or 50 mg bid (in cohort 2 of Phase I and in Phase II) orally on day 8-21 during the first cycle and continuously thereafter. Fourteen patients were enrolled in the phase I and 40 in the phase II. Overall response rate was 26%. The median remission duration (RD) was 20 weeks and was significantly longer in patients with FLT3 mutations not previously exposed to other FLT3 inhibitors (P=0.05) and in patients not previously transplanted (P=0.01). Thirty-two (59%) patients have died, all of complications related to disease progression. G3-4 nonhematological toxicity was reported in 38 (70%) patients, most frequently infections (56%), ejection fraction reduction (11%), and diarrhea or nausea/vomiting (9% each). The combination of midostaurin and AZA is an effective and safe regimen in patients with AML and high-risk MDS. Patients with FLT3 mutations but not previously exposed to other FLT3 inhibitors and patients not previously transplanted derived the greatest benefit. Further studies with this combination are warranted.

UR - http://www.scopus.com/inward/record.url?scp=84925345011&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925345011&partnerID=8YFLogxK

U2 - 10.1002/ajh.23924

DO - 10.1002/ajh.23924

M3 - Article

C2 - 25530214

AN - SCOPUS:84925345011

VL - 90

SP - 276

EP - 281

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 4

ER -